Data published in the medical journal The Lancet showed a significant reduction of kidney tumors due to tuberous sclerosis complex (TSC) in patients enrolled in a phase 3 trial of Novartis' (NYSE:NVS) drug Afinitor, the company announced in a press statement released Thursday.
TSC, a rare disease that Novartis says affects between 1 million and 2 million people across the globe, is a genetic disorder that can cause non-malignant tumors to grow in various parts of the body, including the kidneys. The EXIST-2 phase 3 trial for Afinitor showed a response rate of 42% of patients taking the drug, compared to 0% taking a placebo.
The findings are one more piece of data to support Afinitor, which has already received regulatory approval to treat these tumors in both the United States and European Union.
Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.